Continued treatment with Briumvi provided sustained clinical benefits to patients with relapsing MS, particularly when ...
During year 5 of treatment with BRIUMVI the annualized relapse rate was 0.020, equivalent to one relapse occurring every 50 years of patient ...
Lower nucleus accumbens volume independently predicts depressive symptoms and future anhedonia in patients with early relapsing-remitting MS.
Findings confirmed the approved 600mg IV dose was optimal for slowing disability progression in relapsing MS. A phase 3 study evaluating a higher dose of ocrelizumab in adults with relapsing multiple ...
DelveInsight’s 'Relapsing-Remitting Multiple Sclerosis Pipeline Insight – 2023' report provides comprehensive global coverage of available, marketed, and pipeline relapsing-remitting multiple ...
The National Institute for Health and Care Excellence (NICE) has recommended ublituximab (Briumvi) for treating people with relapsing remitting multiple sclerosis (MS). The drug should be available ...
WEST PALM BEACH, Fla. -- The investigational oral Bruton's tyrosine kinase (BTK) inhibitor evobrutinib failed to distinguish itself from teriflunomide (Aubagio) in two phase III trials of relapsing ...
The neurological disease affects approximately 2.8 million people worldwide The neurological disease affects approximately 2.8 million people worldwide Sanofi has reported positive new data from a mid ...
Please provide your email address to receive an email when new articles are posted on . A phase 2 study included 129 individuals with MS randomized to receive frexalimab or placebo for 24 weeks.
SAN DIEGO -- Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple sclerosis (SPMS), the phase III HERCULES trial showed. The Bruton's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results